Quarterly report · Q1
6960.TEDINET S100RK6N
Period2023-04-01 → 2023-06-30
Filed2023-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥29.2bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥134.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥5.1bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥5.2bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥25.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.4bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥204.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥206.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥191.7bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥40.2bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥43.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥164.3bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥163.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥149.8bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥70.2bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥68.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥115.54 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥571.25 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.27 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 80.3% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥8.4bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥8.4bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥14.1bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥14.1bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.6bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.6bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥257m |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥754m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥29.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥29.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.8bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.8bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥817m |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥282m |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥583m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥4.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 356
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |